Study of Activated Bamboo Charcoal and Probiotics Effects on Gut Microbiome, RNA, Metabolites, and Vascular Health in Adults With Chronic Kidney Disease and Peripheral Arterial Disease

What this Trial Is About

This research focuses on patients with chronic kidney disease CKD and peripheral arterial disease PAD, conditions that cause serious health issues and high medical costs in Taiwan. Researchers aim to identify new diagnostic and prognostic markers by analyzing gut microbiome, metabolome, and circulating long non-coding RNAs. The study also explores how these markers relate to the progression and complications of CKD and PAD, especially concerning cardiovascular risks and limb outcomes. Participants are divided into groups, with some receiving activated bamboo charcoal ABC combined with probiotics and others receiving no treatment. ABC is given as 4g particles containing 2g of charcoal three times daily for six months. Probiotics are administered as 0.8g powder once daily during the last three months of treatment, except for specific subgroups. This design allows evaluation of the therapeutic effects of ABC and probiotics on kidney, vascular, and cardiovascular health. During the study, participants will undergo assessments including changes in 6-minute walking distance, ankle-brachial index ABI, vascular duplex ultrasound, and serum long non-coding RNA levels at baseline, 3 months, 6 months, and annually up to 3 years. Researchers will monitor the impact on renal function, vascular health, cardiovascular events, and mortality. This comprehensive approach combines molecular biology and clinical research to improve care and outcomes for CKD patients with PAD.

Oral Absorbent and Probiotics in CKD Patients With PAD on Gut Microbiota, IncRNA, Metabolome, and Vascular Function